MedTrace Logo

Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

NCT04075331 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2026-04-24

Study results available
· View outcomes & findings →

Summary

This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.

Conditions

Interventions

DRUG

Mepolizumab

Mepolizumab 100mg subcutaneous injection

DRUG

Placebo

Saline solution for subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Christopher Brightling · University of Leicester

  • Neil Greening · University of Leicester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2024-06-21
Completion
2024-06-21

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04075331 on ClinicalTrials.gov